ABT 737

ABT 737 

To Order Contact us: caitlyn@ucb-bioproducts.com

ABT-737

2463-5
EUR 207

ABT

B7737-5.1 10 mM (in 1mL DMSO)
EUR 108

ABT

B7737-50 50 mg
EUR 125

ABT-046

HY-15197 10mM/1mL
EUR 420

ABT-670

HY-19483 1mg
EUR 849

ABT-639

HY-19721 100mg
EUR 2943

ABT-239

HY-12195 10mg
EUR 337

ABT-751

HY-13270 50mg
EUR 394

ABT-072

HY-101634 10mg
EUR 1399

ABT-751

E1KS1165 10mg
EUR 521

ABT-492

E1KS1553 5mg
EUR 1111

Abt-869

20-abx182361
  • EUR 1803.00
  • EUR 551.00
  • 100 mg
  • 10 mg

Abt-199

abx184638-1g 1 g
EUR 648

ABT-199

A8194-1 1 mg
EUR 131
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-5 5 mg
EUR 270
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-5.1 10 mM (in 1mL DMSO)
EUR 421
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-50 50 mg
EUR 838
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-500 500 mg
EUR 1442
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-199

A8194-S Evaluation Sample
EUR 81
Description: ABT-199, developed through a structure-based reverse engineering process, is a novel and specific inhibitor of B-cell lymphoma/leukemia 2 (BCL-2) maintaining a sub-nanomolar affinity towards BCL-2 and over three orders of magnitude less affinity towards BCL-XL

ABT-494

B1947-25
EUR 892

ABT-494

B1947-5
EUR 262

ABT-869

1615-1
EUR 213

ABT-869

1615-5
EUR 615

ABT-888

1620-1
EUR 218

ABT-888

1620-5
EUR 615

ABT-263

2467-25
EUR 805

ABT-263

2467-5
EUR 262

ABT-639 hydrochloride

HY-101616 20mg
EUR 13439

ABT-702 dihydrochloride

HY-103161 100mg
EUR 1313

ABT-263 (Navitoclax)

E1KS1001 5mg
EUR 521

Linifanib (ABT-869)

E1KS1003 5mg
EUR 521

ABT-888 (Veliparib)

E1KS1004 5mg
EUR 325

Lopinavir(ABT-378)

E1KS1380 10mg
EUR 403

Paritaprevir(ABT-450)

20-abx184297
  • EUR 1247.00
  • EUR 913.00
  • 10 mg
  • 5 mg

ABT 724 trihydrochloride

B6981-10 10 mg
EUR 308
Description: ABT 724 trihydrochloride is a highly selective D4 dopamine agonist [1][2], with an EC50 of 281 nM in increasing the binding activity of GTP?S in CHO cells transfected with human D4 receptors, and of 12.4 nM in increasing Ca2+ influx of HEK-293 cells co-transfected with a G protein (G?q05).

ABT 724 trihydrochloride

B6981-50 50 mg
EUR 1136
Description: ABT 724 trihydrochloride is a highly selective D4 dopamine agonist [1][2], with an EC50 of 281 nM in increasing the binding activity of GTP?S in CHO cells transfected with human D4 receptors, and of 12.4 nM in increasing Ca2+ influx of HEK-293 cells co-transfected with a G protein (G?q05).

Zotarolimus(ABT-578)

B4786-25 25 mg
EUR 741
Description: Zotarolimus(ABT-578) is an anti-proliferative drug used exclusively in coronary drug eluting stent [1]. Zotarolimus(ABT-578) is an analogue of rapamycin and an anti-proliferative drug.

Zotarolimus(ABT-578)

B4786-5 5 mg
EUR 347
Description: Zotarolimus(ABT-578) is an anti-proliferative drug used exclusively in coronary drug eluting stent [1]. Zotarolimus(ABT-578) is an analogue of rapamycin and an anti-proliferative drug.

ABT 702 dihydrochloride

B5298-10 10 mg
EUR 412
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 702 dihydrochloride

B5298-100 100 mg
EUR 1708
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 702 dihydrochloride

B5298-5 5 mg
EUR 276
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 702 dihydrochloride

B5298-5.1 10 mM (in 1mL DMSO)
EUR 316
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT 702 dihydrochloride

B5298-50 50 mg
EUR 1181
Description: IC50: 1.7 nM for adenosine kinaseAdenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.

ABT-751 (E7010)

A1493-10 10 mg
EUR 148
Description: ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic agent [1][2].Microtubules are major structure of cells.

ABT-751 (E7010)

A1493-100 100 mg
EUR 595
Description: ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic agent [1][2].Microtubules are major structure of cells.

ABT-751 (E7010)

A1493-5.1 10 mM (in 1mL DMSO)
EUR 177
Description: ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic agent [1][2].Microtubules are major structure of cells.

Linifanib (ABT-869)

A2949-100 100 mg
EUR 780
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

Linifanib (ABT-869)

A2949-25 25 mg
EUR 328
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

Linifanib (ABT-869)

A2949-5 5 mg
EUR 142
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

Linifanib (ABT-869)

A2949-5.1 10 mM (in 1mL DMSO)
EUR 195
Description: Linifanib (ABT-869) is an effective ATP-competitive tyrosine kinase inhibitor against the platelet-derived growth factor (PDGF) receptor and the vascular endothelial growth factor receptor (VEGFR) families, including constitutively active FMS-like receptor tyrosine kinase 3 (FLT3) [1][2].

ABT-888 (Veliparib)

A3002-10 10 mg
EUR 148
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)

A3002-200 200 mg
EUR 835
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)

A3002-5 5 mg
EUR 125
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)

A3002-5.1 10 mM (in 1mL DMSO)
EUR 160
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)

A3002-50 50 mg
EUR 351
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-888 (Veliparib)

A3002-S Evaluation Sample
EUR 81
Description: ABT-888, also named as Veliparib, is poly (ADP-ribose) polymerase (PARP) inhibitor and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents.

ABT-263 (Navitoclax)

A3007-10 10 mg
EUR 131
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-100 100 mg
EUR 456
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-1000 1 g
EUR 3298
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-5 5 mg
EUR 108
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-5.1 10 mM (in 1mL DMSO)
EUR 166
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-50 50 mg
EUR 282
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

ABT-263 (Navitoclax)

A3007-S Evaluation Sample
EUR 81
Description: ABT-263 is an orally sellecitive inhibitor of B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974.

EZSolution?ABT-494 (Upadacitinib)

B2486-5
EUR 272

Zinc Finger Protein 737 (ZNF737) Antibody

abx030856-400ul 400 ul
EUR 523

Zinc Finger Protein 737 (ZNF737) Antibody

abx030856-80l 80 µl
EUR 286

BCl-2 Inhibitor, ABT-199

2253-1
EUR 147

BCl-2 Inhibitor, ABT-199

2253-5
EUR 311

Recombinant (Sf9) Human Phosphoinositide 3-kinase p110g inactive mutant

RP-737 1 ug
EUR 286

IL-33 Recombinant Protein (Animal Free)

40-737 2 ug
EUR 269.75
Description: Human IL-33 is a proinflammatory protein that shares structural and functional characteristics with the IL-1 cytokine family. It binds and signals through the IL-1RL1/ST2 receptor, to activate NF-κB and MAP kinases. IL-33 induces production of TH2 cell related cytokines, including IL-4, IL-5 and IL-13, and exerts multiple inflammation related bioactivities. Recombinant Human IL-33 is a 17.9 kDa protein containing 159 amino acid residues.

SARS-CoV-2 (COVID-19) S Protein RBD-SD1 Recombinant Protein

92-737 0.02 mg
EUR 464
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Recombinant Mycobacterium Vanbaalenii katG2 Protein (aa 1-737)

VAng-Yyj5075-inquire inquire Ask for price
Description: Mycobacterium Vanbaalenii (strain DSM 7251 / PYR-1) Catalase-peroxidase 2 (katG2), recombinant protein.

Recombinant Streptococcus Pneumoniae pnp Protein (aa 1-737)

VAng-Ly1222-inquire inquire Ask for price
Description: Streptococcus Pneumoniae Polyribonucleotide nucleotidyltransferase, partial, recombinant protein.

Recombinant Schizosaccharomyces Pombe SPBC16H5.12c Protein (aa 1-737)

VAng-Yyj6177-inquire inquire Ask for price
Description: Schizosaccharomyces Pombe (strain 972 / ATCC 24843) (Fission yeast) Uncharacterized protein C16H5.12c (SPBC16H5.12c), recombinant protein.

Recombinant Mycobacterium Bovis recG Protein (aa 1-737)

VAng-Yyj3541-inquire inquire Ask for price
Description: Mycobacterium Bovis ATP-dependent DNA helicase recG (recG), recombinant protein.

Recombinant Mycoplasma Pneumoniae MPN_370 Protein (aa 1-737)

VAng-Lsx04929-inquire inquire Ask for price
Description: Mycoplasma Pneumoniae (strain ATCC 29342 / M129) Putative adhesin P1-like protein MPN_370, recombinant protein.

Recombinant Caenorhabditis Elegans R05D3.2 Protein (aa 1-737)

VAng-Ly3607-inquire inquire Ask for price
Description: Caenorhabditis Elegans LIMR family protein R05D3.2 (R05D3.2), partial, recombination protein.

Human Zinc finger protein 737, ZNF737 ELISA KIT

ELI-44407h 96 Tests
EUR 824

Anti-EGFR (ABT-806)-Mc-MMAF ADC

ADC-W-515 1mg Ask for price
Description: This ADC product is comprised of an anti-EGFR monoclonal antibody (ABT-806) conjugated via a MC linker to MMAF

Recombinant Streptococcus Pneumoniae pnp Protein (aa 1-737) (strain JJA)

VAng-Ly1675-inquire inquire Ask for price
Description: Streptococcus Pneumoniae (strain JJA) Polyribonucleotide nucleotidyltransferase, partial, recombinant protein.

Geneticin (G418, (>98% pure))

ABT-800-01 1 g
EUR 164

Geneticin (G418, (>98% pure))

ABT-800-05 5 g
EUR 408

5-Bromo-5-nitro-1,3-dioxane (BND)

ABT-810-01 1 g
EUR 141

5-Bromo-5-nitro-1,3-dioxane (BND)

ABT-810-10 5 g
EUR 263

ABT 737